Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0106213793
Wed, 08.02.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, February 8, 2023
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
SGI debt facility to provide Spexis up to half of the projected ColiFin® Phase 3 developm [ … ]
Mon, 09.01.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, January 9, 2023Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
Inhaled murepavadin shown to be well tolerated at all dose levels
Program derived from Spexis’ macrocycle platform
Data suppor [ … ]
Thu, 22.09.2022
Spexis AG
Allschwil, Switzerland, September 22, 2022
Spexis announces positive renal impairment clinical trial results with balixafortide
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated
Safety findings support potential to use significantly higher doses of balixafortide than those previous [ … ]
Thu, 22.09.2022
Spexis AG
Allschwil, Switzerland, September 22, 2022
Spexis announces positive renal impairment clinical trial results with balixafortide
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated
Safety findings support potential to use significantly higher doses of balixafortide than those previous [ … ]
Tue, 06.09.2022
Spexis AG
Allschwil, Switzerland, September 06, 2022
Spexis provides business update and announces financial results for the first half of 2022
Study start-up activities nearly complete for COPILOT, the first part of the Phase 3 ColiFin® program, including regulatory and ethics committee approvals of trial sites
Enrollment of Phase 1 trial of inhaled mur [ … ]
Tue, 06.09.2022
Spexis AG
Allschwil, Switzerland, September 06, 2022
Spexis provides business update and announces financial results for the first half of 2022
Study start-up activities nearly complete for COPILOT, the first part of the Phase 3 ColiFin® program, including regulatory and ethics committee approvals of trial sites
Enrollment of Phase 1 trial of inhaled mur [ … ]
Thu, 28.07.2022
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, July 28, 2022
Spexis provides business update
Cash position to finance operations extended into January 2023
Resources focused on advancing lead program, Phase 3 ColiFin®
Assessment of balixafortide development options continues; balixafortide PK/safety clinical trial in renall [ … ]
Thu, 28.07.2022
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, July 28, 2022
Spexis provides business update
Cash position to finance operations extended into January 2023
Resources focused on advancing lead program, Phase 3 ColiFin®
Assessment of balixafortide development options continues; balixafortide PK/safety clinical trial in renall [ … ]
Wed, 27.04.2022
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 27, 2022
Spexis Annual General Meeting 2022
Spexis AG (SIX: SPEX) today announced that its shareholders approved all proposals of the Board of Directors at the 25th Annual General Meeting (AGM) with a significant majority. In line with the COVID-19 Ordinance 3 of the Swiss [ … ]
Fri, 01.04.2022
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 1, 2022
Spexis publishes invitation to Annual General Meeting 2022
- Pre-AGM information call on April 7, 2022 at 2:30PM CET
- AGM to be held April 26, 2022
- Shareholders not physically present, in accordance with COVID-19 ordinances
Spexis AG (SIX: SPEX) a clinical-sta [ … ]